(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | |
---|---|---|---|---|---|---|---|---|
Turnover | --206.86B | 8.08%134.41B | -3.39%258.41B | --124.37B | --61.05B | 29.11%267.49B | 34.55%207.19B | --153.99B |
Operating income | 206.86B | 8.08%134.41B | -3.39%258.41B | 124.37B | 61.05B | 29.11%267.49B | 34.55%207.19B | 153.99B |
Cost of sales | ---178.48B | -7.73%-116.1B | 3.71%-225.78B | ---107.77B | ---52.67B | -29.25%-234.48B | -40.13%-181.41B | ---129.46B |
Operating expenses | -178.48B | -7.73%-116.1B | 3.71%-225.78B | -107.77B | -52.67B | -29.25%-234.48B | -40.13%-181.41B | -129.46B |
Gross profit | 28.38B | 10.34%18.31B | -1.15%32.63B | 16.6B | 8.38B | 28.07%33.01B | 5.09%25.78B | 24.53B |
Selling expenses | ---2.24B | -5.61%-1.47B | -7.45%-2.99B | ---1.39B | ---690.57M | 1.90%-2.78B | -26.00%-2.84B | ---2.25B |
Administrative expenses | ---13.64B | -0.55%-9.05B | -0.40%-17.77B | ---9B | ---4.78B | -17.07%-17.69B | -29.80%-15.12B | ---11.64B |
Research and development expenses | ---1.92B | -10.76%-1.3B | -2.81%-2.29B | ---1.17B | ---596.6M | -3.16%-2.22B | -23.73%-2.15B | ---1.74B |
Impairment and provision | ---239.71M | -342.15%-159.87M | 104.06%33.48M | --66.02M | ---5.13M | -42.31%-825.17M | -22.14%-579.85M | ---474.76M |
-Other impairment is provision | ---239.71M | -342.15%-159.87M | 104.06%33.48M | --66.02M | ---5.13M | -42.31%-825.17M | -22.14%-579.85M | ---474.76M |
Special items of operating profit | --1.21B | -23.82%866.54M | -19.13%2.69B | --1.14B | --490.29M | -17.80%3.33B | 85.51%4.05B | --2.18B |
Operating profit | 11.55B | 15.48%7.2B | -3.88%12.31B | 6.23B | 2.8B | 40.23%12.81B | -13.79%9.14B | 10.6B |
Financing income | --486.91M | 41.73%415.06M | 83.23%633.37M | --292.85M | --137.61M | 84.06%345.66M | 1.12%187.79M | --185.71M |
Financing cost | ---1.8B | -12.65%-1.23B | -10.48%-2.27B | ---1.09B | ---541.07M | -31.44%-2.05B | -11.12%-1.56B | ---1.41B |
Share of profits of associates | ---50.38M | -364.04%-62.58M | -990.05%-67.19M | ---13.49M | ---12.57M | -82.30%7.55M | 295.52%42.66M | ---21.82M |
Special items of earning before tax | ---30M | ---- | -70.97%-123.91M | ---- | ---- | -38.35%-72.47M | -1,315.78%-52.38M | ---3.7M |
Earning before tax | 10.15B | 16.60%6.32B | -4.99%10.49B | 5.42B | 2.38B | 42.41%11.04B | -17.11%7.75B | 9.35B |
Tax | ---2.47B | -2.16%-1.56B | 35.32%-2.57B | ---1.53B | ---707.15M | -18.17%-3.98B | -14.80%-3.37B | ---2.93B |
After-tax profit from continuing operations | 7.67B | 22.26%4.76B | 12.11%7.91B | 3.89B | 1.67B | 61.04%7.06B | -31.70%4.38B | 6.42B |
Earning after tax | 7.67B | 22.26%4.76B | 12.11%7.91B | 3.89B | 1.67B | 61.04%7.06B | -31.70%4.38B | 6.42B |
Minority profit | --55.88M | 83.76%-45.79M | -138.91%-322.88M | ---282.04M | ---46.13M | 337.18%829.86M | 11.21%-349.89M | ---394.05M |
Profit attributable to shareholders | 7.62B | 15.10%4.81B | 32.24%8.23B | 4.18B | 1.72B | 31.60%6.23B | -30.51%4.73B | 6.81B |
Basic earnings per share | 1.58 | 16.28%1 | 32.81%1.7 | 0.86 | 0.35 | 24.27%1.28 | -32.68%1.03 | 1.53 |
Diluted earnings per share | 1.58 | 16.28%1 | 32.81%1.7 | 0.86 | 0.35 | 24.27%1.28 | -32.24%1.03 | 1.52 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion |
Auditor | -- | -- | PricewaterhouseCoopers | -- | -- | PricewaterhouseCoopers | PricewaterhouseCoopers | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data